| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514200900 | Cyclopeptide utilizing | 74 |
| 20100240596 | REPAIR OF RUPTURED MEMBRANE BY INJECTION OF NATURALLY OCCURRING PROTEIN IN AMNIOTIC FLUID SAC - The present invention provides compositions and methods for use in treatment of premature rupture of membrane. The compositions of the invention include a therapeutic amount of an avian thick egg white composition. Preferably, the compositions include the purified thick egg white protein, ovomucin. The methods of the invention involve injecting an effective amount of the compositions into the prematurely ruptured amniotic sac of a patient in order to seal the rupture. | 09-23-2010 |
| 20100279952 | CROSS-LINKED HYDROGEL CONTAINING AN ACTIVE SUBSTANCE - The invention relates to a biocompatible metastable intermediate material for controlling the mobility of at least one biologically active substance. An example of the invention is a hydrogel formed by cross-linked sodium hyaluronate treated with an oxidizing agent so as to open sugar rings and form aldehyde groups. The gel according to the invention is sterilized, e.g. by autoclaving. | 11-04-2010 |
| 20100286066 | Alpha 1-Antitrypsin Compositions and Treatment Methods Using Such Compositions - Alpha 1-antitrypsin compositions and treatment methods using such compositions for treating a variety of pulmonary diseases are provided. The compositions generally contain AAT, a stabilizing carbohydrate such as trehalose, a surfactant such as Polysorbate 80 and an antioxidant to stabilize AAT for use as a therapeutic. The formulations can be prepared as both liquids and solids and administered by nebulization of the liquid formulation or by conversion of dry powder formulation into an aerosol. | 11-11-2010 |
| 20100286067 | GLYCOCONJUGATION OF POLYPEPTIDES USING OLIGOSACCHARYLTRANSFERASES - The current invention provides polypeptides and polypeptide conjugates that include an exogenous N-linked glycosylation sequence. The N-linked glycosylation sequence is preferably a substrate for an oligosaccharyltransferase (e.g., bacterial PgIB), which can catalyze the transfer of a glycosyl moiety from a lipid-bound glycosyl donor molecule (e.g., a lipid-pyrophosphate-linked glycosyl moiety) to an asparagine (N) residue of the glycosylation sequence. In one example, the asparagine residue is part of an exogenous N-linked glycosylation sequence of the invention. The invention further provides methods of making the polypeptide conjugates that include contacting a polypeptide having an N-linked glycosylation sequence of the invention and a lipid-pyrophosphate-linked glycosyl moiety (or phospholipid-linked glycosyl moiety) in the presence of an oligosaccharyltransferase under conditions sufficient for the enzyme to transfer the glycosyl moiety to an asparagine residue of the N-linked glycosylation sequence. Exemplary glycosyl moieties that can be conjugated to the glycosylation sequence include GlcNAc, GlcNH, bacillosamine, 6-hydroybacillosamine, GalNAc, GaINH, GlcNAc-GlcNAc, GlcNAc-GlcNH, GlcNAc-Gal, GlcNAc-GlcNAc-Gal-Sia, GlcNAc-Gal-Sia, GlcNAc-GlcNAc-Man, and GlcNAc-GlcNAc-Man(Man)2. The transferred glycosyl moiety is optionally modified with a modifying group, such as a polymer (e.g., PEG). In one example, the modified glycosyl moiety is a GIcNAc or a sialic acid moiety. | 11-11-2010 |
| 20100292168 | Protein Mixture and Use Thereof in the Preparation of a Product that is Intended for Oral or Enteral Administration - This invention relates to a novel protein mixture and the use thereof in the preparation of a food product intended for oral or enteral nutrition. This protein mixture, based on caseinate, pea proteins and milk serum proteins has very high protein quality indices (protein efficiency index) and a good digestibility, thus the ease of conversion of said protein mixture is very good when compared to that of superior-quality highly-digestible proteins per excellence. | 11-18-2010 |
| 20100298236 | SOLUBLE GP130 MUTEINS WITH IMPROVED BINDING ACTIVITY - Described are soluble gp130 polypeptide monomers and dimers, wherein, in a preferred embodiment, at least one of the three amino acid residues Thr | 11-25-2010 |
| 20100305048 | NOVEL USE OF CYTOKINE INHIBITORS - The use of substance that inhibits a pro-inflammatory cytokine, such as TNF or IL-1, for the production of a pharmaceutical composition for improving wound healing is disclosed. Also, a method for improving wound healing wherein a therapeutically effective amount of a substance that inhibits a pro-inflammatory cytokine is administered to a patient in need of said treatment is disclosed. | 12-02-2010 |
| 20100311670 | Conjugates of hydroxyalkyl starch and a protein, prepared by native chemical ligation - Conjugates of an active substance and hydroxyalkyl starch (HAS) are provided herein. The active substance and the HAS are linked by a chemical moiety having a structure according to formula (I) wherein Y is O or S, and X is SH or (F). The conjugate has a structure according to formula (IV) wherein HAS′ is a residue of HAS or a derivative thereof linked to the thioester group, and AS′ is a residue of the active substance or derivative thereof linked to the alpha-X beta-amino group; or a structure according to formula (V) wherein HAS′ is a residue of HAS or derivative thereof linked to the alpha-X beta-amino group, and AS′ is a residue of the active substance or derivative thereof linked to the thioester group, and wherein the group —(C═Y) is derived from the thioester group —(C═Y)—S—R′ and the group HN—CH—CH | 12-09-2010 |
| 20100317596 | SERUM AMYLOID P DERIVATIVES AND THEIR PREPARATION AND USE - One aspect of the present invention relates to the surprising discovery that modification of a glycan structure on a human SAP polypeptide can increase the biological activity of the SAP polypeptide relative to a corresponding sample of wild-type SAP isolated from human serum. The disclosure provides both variant human SAP polypeptides and methods for making the same. In particular, the present invention provides methods and compositions for in vitro and in vivo addition, deletion, or modification of sugar residues to produce SAP polypeptides, such as a human SAP polypeptide, having a desired glycosylation pattern. | 12-16-2010 |
| 20100317597 | GLYCOMACROPEPTIDE MEDICAL FOODS FOR NUTRITIONAL MANAGEMENT OF PHENYLKETONURIA AND OTHER METABOLIC DISORDERS - Medical foods containing glycomacroprotein and additional supplemented amounts of arginine, leucine, and optionally other amino acids, such as tyrosine, are disclosed. The medical foods can be used to provide the complete protein requirements for patients having metabolic disorders such as phenylketonuria. | 12-16-2010 |
| 20100323973 | CONJUGATES CONTAINING HYDROPHILIC SPACER LINKERS - Described herein are compositions and methods for use in targeted drug delivery using cell receptor binding drug delivery conjugates containing hydrophilic spacer linkers for use in imaging, diagnosing, and/or treating diseases and disease states caused by pathogenic cell populations. | 12-23-2010 |
| 20110028407 | ENHANCEMENT OF INNATE RESISTANCE TO INFECTION - The present invention provides compounds and compositions that enhance the innate immune system. The present invention comprises methods of preventing, treating or ameliorating an infectious disease comprising administering said compounds to a subject. The invention also comprises methods of formulation and administration of said compounds. | 02-03-2011 |
| 20110028408 | DIAGNOSTIC MOLECULE AND THERAPEUTIC TARGET - Provided herein are methods and compositions for regulating airway tissue remodelling and for treating or preventing conditions associated with airway inflammation and/or airway tissue remodelling. The methods comprise normalising fibulin-1 levels in said tissue relative to normal endogenous levels. In an embodiment the methods comprise administering to a subject in need thereof an effective amount of at least one agent capable of inhibiting the expression and/or activity of fibulin-1. | 02-03-2011 |
| 20110034400 | COMPOSITIONS AND METHODS FOR ANALYZING BACTERIAL ADHERENCE AND ANTI-ADHERENCE TO MUCUS, EPITHELIAL CELLS AND OTHER CELLS - The present invention generally relates to methods for detecting, identifying, and measuring bacterial adherence to mucus and epithelial cells. In particular, the present invention provides assays for detecting and identifying the presence or absence of bacterial adherence to mucus (epithelial cells (e.g., present in the intestines), or other portion of an animal where bacteria may be present, and methods for identifying and characterizing (e.g., the efficacy of) modulators of bacterial adherence to mucus and epithelial cells, or other portion of the animal where bacteria may be present. | 02-10-2011 |
| 20110077208 | EXPRESSION OF SECRETED HUMAN ALPHA-FETOPROTEIN IN TRANSGENIC ANIMALS - The invention features a process of expressing secreted recombinant human alpha-fetoprotein (rHuAFP) in the milk or urine of transgenic mammals. | 03-31-2011 |
| 20110077209 | PROTEIN OR GLYCOPROTEIN FROM HALIOTIS MIDAE AND ITS USE AS AN IMMUNOTHERAPY AGENT - Disclosed is a protein or glycoprotein obtainable from a crude extract of Haliotis midae, with a molecular weight of approx. 30 kDa and an isoelectric point of around 4.3-4.5, possessing passive cutaneous anaphylaxis-inhibiting activity. | 03-31-2011 |
| 20110082092 | INTERFERING RNA DELIVERY SYSTEM AND USES THEREOF - The invention provides a delivery system comprising a cell penetrating peptide, a polyarginine peptide, and an interfering RNA molecule. The system can be used for delivering interfering RNA molecules into a cell in vivo or in vitro. Therapeutic uses for the delivery system are also provided. | 04-07-2011 |
| 20110086808 | MODIFIED THERAPEUTIC AGENTS - The invention provides a modified therapeutic agent, said modified agent comprising three or more membrane binding elements with low membrane affinity covalently associated with the agent which elements are capable of interacting independently and with thermodynamic additivity, with components of cellular or artificial membranes exposed to extracellular fluids wherein at least two membrane binding elements are lipophilic elements, which may be aliphatic acyl groups, which may be selected from the list consisting of Myristoyl, Decanoyl or Hexanoyl. | 04-14-2011 |
| 20110092444 | LARGE SCALE PREPARATION OF ALPHA-1 PROTEINASE INHIBITOR AND USE THEREOF - A pharmaceutical preparation containing a purified, active API in the form of a ready to use sterile solution that optionally includes an excipient, diluent or a carrier. At least 90% to 95% of the API is active and is present at a concentration between about 1% to about 10%. The pH of the preparation is in the range of 6.5-7.5 and the preparation is preferably devoid of a protein stabilizer. The API is stable for at least 3 months when stored at a temperature of between 20° C. to 25° C. and is stable for a minimum of at least 12 months, at least 21 months, or at least 36 months when the pharmaceutical composition is stored at a temperature of between 2° C. to 8° C. The composition is formulated to be administered intravenously or by inhalation. | 04-21-2011 |
| 20110105412 | CONJUGATED MOLECULES COMPRISING A PEPTIDE DERIVED FROM THE CD4 RECEPTOR COUPLED TO A POLYANION FOR THE TREATMENT OF AIDS - This invention relates to a conjugated molecule comprising a peptide derived from the CD4 receptor coupled to an organic molecule by means of a linker as well as a process for its preparation. Such a conjugated molecule can be used in antiviral treatment, namely in the treatment of AIDS. | 05-05-2011 |
| 20110105413 | POLYMERIC SYSTEMS CONTAINING INTRACELLULAR RELEASABLE DISULFIDE LINKER FOR THE DELIVERY OF OLIGONUCLEOTIDES - The present invention provides polymeric prodrugs including an intracellular releasable disulfide linker for the delivery of oligonucleotides. Methods of making the compounds as well as methods of delivering nucleic acids to tumor cells in a mammal using the same are also provided. | 05-05-2011 |
| 20110112039 | Polysaccharides comprising carboxyl functional groups substituted via esterification by a hydrophobic alcohol - Polysaccharide including carboxyl functional groups. The polysaccharide being chosen from the group of anionic synthetic polysaccharides including 1,6 bonds obtained from neutral polysaccharides of which at least one of a carboxyl functional groups is esterified by a hydrophobic alcohol (-Ah) (residue of a hydrophobic alcohol). The hydrophobic alcohol (Ah) being grafted or bonded to the anionic polysaccharide by a function F (ester function), which results from coupling between the carboxylate function of the anionic polysaccharide and hydroxyl function of the hydrophobic alcohol. Carboxyl functions of anionic polysaccharide, which are not substituted, are in the form of carboxylate of a cation. The polysaccharide including carboxyl functional groups are amphiphilic at neutral pH. | 05-12-2011 |
| 20110112040 | SUPERCHARGED PROTEINS FOR CELL PENETRATION - Compositions, systems and related methods for delivering a supercharged protein or a complex of a supercharged protein and therapeutic agent (e g, nucleic acid, peptide, small molecule) to cells are disclosed. Superpositively charged proteins may be associated with nucleic acids (which typically have a net negative charge) via electrostatic interactions. The systems and methods may involve altering the primary sequence of a protein in order to “supercharge” the protein (e g, to generate a superpositively-charged protein). The compositions may be used to treat proliferative diseases, infectious diseases, cardiovascular diseases, inborn errors in metabolism, genetic diseases, etc. | 05-12-2011 |
| 20110124576 | Transferrin Variants and Conjugates - Based on the three-dimensional structure of transferrin, the inventors have designed variant polypeptides (muteins) which have one or more Cysteine residues with a free thiol group (hereinafter referred to as thiotransferrin). The variant polypeptide may be conjugated through the sulphur atom of the Cysteine residue to a bioactive compound. | 05-26-2011 |
| 20110124577 | PREPARATION FOR ORAL ADMINISTRATION COMPRISES QUERCETIN GLYCOSIDE AND A WATER-BASED SOLVENT EXTRACT OF CARTILAGE CONTAINING CHONDROITIN SULFATE - It is an object of the present invention to provide a preparation for oral administration in which the bitter taste derived from quercetin glycoside is improved. | 05-26-2011 |
| 20110130346 | PEPTIDE CONJUGATES FOR DELVERY OF BIOLOGICALLY ACTIVE COMPOUNDS - A construct comprising a cell delivery peptide covalently attached to a biologically active compound suitable for delivery of said biologically active compound into cells, wherein optionally the cells are cardiac muscle, skeletal muscle, smooth muscle or contractile cells. | 06-02-2011 |
| 20110136745 | METHOD OF SELECTING SOYBEANS WITH ENHANCED BIOACTIVITY AND COMPOSITIONS FOR REDUCING CANCER CELL VIABILITY - The invention provides a method that uses enzyme-treatment of whole soybeans or partially defatted soybeans to select soybeans with improved bioactivity or bioactivities. The invention further provides a soybean plant and seed with a non-transgenic mutation conferring enhanced bioactivity as an hydrolysate when compared to hydrolysate from other seeds, for instance in a cell-based assay, including reduced cancer cell viability; increased LDL receptor activity; reduced lipid accumulation; increased adiponectin expression; decreased FAS and LPL expression; reduced production of NO and PGE | 06-09-2011 |
| 20110166081 | Alpha-dystroglycan as a Protein Therapeutic - Disclosed is alpha-dystroglycan protein (alpha-DG) in glycosylated and functional form. The disclosed alpha-DG binds to the basal lamina and to the sarcolemma of muscle fibers and may be injected into muscle and incorporated into muscle fibers in order to restore membrane integrity where the muscle fibers comprise a dysfunctional alpha-DG protein. Alpha-DG as disclosed herein may be utilized in pharmaceutical compositions and methods for treating diseases and disorders associated with or characterized by a dysfunctional alpha-DG, such as muscular dystrophy. | 07-07-2011 |
| 20110172165 | MODIFIED LINKERS - We describe modified peptide linkers that function to link at least first and second polypeptides wherein said modified peptide linker comprises a motif for the addition of a sugar moiety. | 07-14-2011 |
| 20110172166 | Anionic polysaccharides functionalized by a hydrophobic acid derivative - A novel anionic polysaccharides functionalized by at least one hydrophobic acid derivative. These novel anionic polysaccharides including hydrophobic groups have good biocompatibility and their hydrophobicity can be easily adjusted without detrimentally affecting the biocompatibility or the stability. A method of synthesis which makes it possible to produce them and to pharmaceutical compositions including them. | 07-14-2011 |
| 20110178028 | METHOD FOR THE DETECTION OF PROVENTRICULAR DILATATION DISEASE AND KIT THEREOF - A ganglioside or a mixture of gangliosides, isolated from the peripheral and central nervous system of a bird, in particular a parrot, their use for the preparation of a medicament, methods for the diagnosis of Proventricular Dilatation Disease and diagnostic kits thereof, are disclosed. | 07-21-2011 |
| 20110190221 | MODULATION AND REPLETION/ENHANCEMENT OF THE COMPLEMENT SYSTEM FOR TREATMENT OF TRAUMA - The present invention features the use of selected complement activation inhibitor(s) for treating an individual who has suffered a severe injury. The complement activation inhibitor acts at or above the level of C3 activation and does not significantly deplete or irreversibly inhibit complement activation. Also provided are compositions and methods for repleting and/or enhancing complement activation capacity in a subject who has suffered a traumatic injury. | 08-04-2011 |
| 20110190222 | Selective Inhibition of Polyglutamine Protein Expression - The present invention relates to the selective inhibition of protein expression of CAG repeat-related disease proteins such as Huntingtin using nucleic acid analogs. Peptide nucleic acids and locked nucleic acids are particularly useful analogs. | 08-04-2011 |
| 20110195913 | Anionic polysaccharides functionalized by at least two hydrophobic groups carried by an at least trivalent spacer - Anionic polysaccharide derivatives partially functionalized by at least two vicinal hydrophobic groups, the hydrophobic groups, which are identical or different, being carried by an at least trivalent radical or spacer, a method of synthesis of the functionalized polysaccharides, and pharmaceutical compositions having one of the polysaccharides and at least one active principle are provided. | 08-11-2011 |
| 20110212900 | METHOD FOR PROPHYLACTIC AND/OR THERAPEUTIC TREATMENT OF PAIN ASSOCIATED WITH HEMATOPOIETIC CELL TRANSPLANTATION - A method for prophylactic and/or therapeutic treatment of a pain associated with hematopoietic cell transplantation, which comprises the step of administrating thrombomodulin to a mammal. | 09-01-2011 |
| 20110212901 | HYALURONIC ACID DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF - The present invention provides a hydrophobic group-introduced hyaluronic acid derivative comprising at least one repeating unit represented by the formula (I): | 09-01-2011 |
| 20110218156 | MOLECULAR ENTITIES FOR BINDING, STABILIZATION AND CELLULAR DELIVERY OF NEGATIVELY CHARGED MOLECULES - In accordance with the present invention, it has been discovered that the uptake of negatively charged entities into cells can be enhanced by noncovalently associating such charged entities with molecular entities comprising an amphiphilic core with positively charged arms, wherein a plurality of lipophilic (e.g., bile acid) moieties are covalently attached to the positively charged arms. The molecular entities form well defined stoichiometric complexes with negatively charged entities. Various compositions and methods for stabilizing anionic charged entities and for enhancing the cellular uptake of any anionic charged entities, e.g. double-stranded or hairpin nucleic acid, are provided. | 09-08-2011 |
| 20110230425 | COMPOSITIONS FOR PROTECTION AND CELLULAR DELIVERY OF INTERFERING RNA - Compositions and methods for protecting and administering small RNA to preserve stability are described. The small RNAs may either be in unmodified form or may be chemically modified to enhance stability further. | 09-22-2011 |
| 20110237521 | SPLICE SWITCHING OLIGOMERS FOR TNF SUPERFAMILY RECEPTORS AND THEIR USE IN TREATMENT OF DISEASE - Methods and compositions are disclosed for controlling expression of TNF receptors (TNFR1 and TNFR2) and of other receptors in the TNFR superfamily using compounds that modulate splicing of pre-mRNA encoding these receptors. More specifically these compounds cause the removal of the transmembrane domains of these receptors and produce soluble forms of the receptor which act as an antagonist to reduce TNF-α activity or activity of the relevant ligand. Reducing TNF-α activity provides a method of treating or ameliorating inflammatory diseases or conditions associated with TNF-α activity. Similarly, diseases associated with other ligands can be treated in like manner. In particular, the compounds of the invention are splice-splice switching oligomers (SSOs) which are small molecules that are stable in vivo, hybridize to the RNA in a sequence specific manner and, in conjunction with their target, are not degraded by RNAse H. | 09-29-2011 |
| 20110237522 | NEUTRAL NANOTRANSPORTERS - Neutral lipid formulations for nucleic acid delivery are provided according to the invention. The neutral lipid formulations include hydrophobically modified polynucleotides and fat mixtures. Methods of using the neutral lipid formulations are also provided. | 09-29-2011 |
| 20110263514 | DELIVERY OF AGENTS USING INTERFERING NANOPARTICLES - Provided are compositions and methods for delivery of therapeutic agents, such as chemically stabilized antisense oligonucleotides useful in RNA silencing. The compositions include interfering nanoparticles (iNOPs) associated with one or more agents. Several functional iNOP derivatives are provided which allow for targeted delivery of agents to specific cell types as well as exhibiting reduced cellular toxicity. | 10-27-2011 |
| 20110301097 | Oral Administration Of Therapeutic Agent Coupled To Transporting Agent - The present invention is directed toward a composition for widespread distribution, systemic expression and sustained delivery of a therapeutic agent and to a process for administration of a therapeutic agent via a natural gastrointestinal pathway. More particularly, the invention discloses a composition for the administration of oral gene therapy and a process for its production and use. | 12-08-2011 |
| 20110319341 | METHOD OF CONTROLLING PESTS WITH BIOSURFACTANT PENETRANTS AS CARRIERS FOR ACTIVE AGENTS - A penetrating composition can include an active agent that has an activity that is either beneficial for plants or controls pests. The composition can also include a penetrant that is present in an effective amount for carrying the at least one active agent into or through a medium, the medium being at least one of a plant, soil, or pest. Also, penetrating composition can be used for increasing the permeation of an active agent in an animal. The composition includes an active agent having an activity that is beneficial for an animal. Also, the composition includes a penetrant selected from the group consisting of biosurfactants, glycolipids, lipopeptides, favolipids, lipoproteins, phospholipids, lipopolysaccharide-protein complexes, polysaccharide-protein-fatty acid complexes, and combinations thereof. A biosurfactant composition can include an effective amount of a biosurfactant for controlling a pest, preserving a plant cutting, or reducing effects of environmental stress on a plant. | 12-29-2011 |
| 20110319342 | CELL-SPECIFICALLY EFFECTIVE MOLECULES ON THE BASIS OF siRNA AND APPLICATION KITS FOR THE PRODUCTION THEREOF AND USE THEREOF - A biologically inactivated cell-specifically effective molecule for biologically inactive transfection into a target cell to inhibit expression of genes in the target cell after biological activation of the molecule, by bonding to mRNA and with the formation of a RISC complex, the biologically inactivated cell-specifically effective molecule comprising siRNA coupled with at least one peptide via a linker which remains at the siRNA after biological activation of the molecule, the linker comprising an amino Cn linker wherein n is an integer of 1-6. Kits include the molecule or the constituents thereof and transfection reagents in ampoules and injection equipment for injecting mixtures of the ampoule contents into a medium containing a target cell. | 12-29-2011 |
| 20120004183 | Unnatural reactive amino acid genetic code additions - This invention provides compositions and methods for producing translational components that expand the number of genetically encoded amino acids in eukaryotic cells. The components include orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, pairs of tRNAs/synthetases and unnatural amino acids. Proteins and methods of producing proteins with unnatural amino acids in eukaryotic cells are also provided. | 01-05-2012 |
| 20120004184 | TREATMENT OF NUCLEAR FACTOR (ERYTHROID-DERIVED 2)-LIKE 2 (NRF2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO NRF2 - The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Nu-clear factor (erythroid-derived 2)-like 2 (NRF2), in particular, by targeting natural antisense polynucleotides of Nuclear factor (erythroid-derived 2)-like 2 (NRF2). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of NRF2. | 01-05-2012 |
| 20120010155 | GNTIII EXPRESSION IN PLANTS - The invention relates to the field of glycoprotein processing in transgenic plants used as cost efficient and contamination safe factories for the production of recombinant biopharmaceutical proteins or pharmaceutical compositions comprising these glycoproteins. The invention provides a plant comprising a functional mammalian enzyme providing mammalian GnTIII that is normally not present in plants, said plant additionally comprising at least a second mammalian protein or functional fragment thereof that is normally not present in plants. | 01-12-2012 |
| 20120010156 | TREATMENT OF DELTA-LIKE 1 HOMOLOG (DLK1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO DLK1 - The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Delta-like (1) homolog (DLK1), in particular, by targeting natural antisense polynucleotides of Delta-like (1) homolog (DLK1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of (DLK1). | 01-12-2012 |
| 20120028911 | Mucin Derived Polypeptides - The present technology relates to isolated MUC17, Muc3 or MUC3 derived polypeptides and polynucleotides encoding the same. The MUC17, Muc3 or MUC3 derived polypeptides and polynucleotides can be used to treat gastrointestinal tract diseases and disorders. Also described herein are pharmaceutical compositions comprising MUC17, Muc3 or MUC3 derived polypeptides and/or polynucleotides encoding the same alone or in combination along with a pharmaceutically acceptable carrier, diluent or excipient for the treatment of gastrointestinal disorders and diseases, including, irritable bowel disease and its associated colitides, for example, Crohn's Disease. | 02-02-2012 |
| 20120035115 | CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION - The invention features compounds of formula I or II: | 02-09-2012 |
| 20120046235 | Conjugates of hydroxyalkyl starch and a protein, prepared by native chemical ligation - Conjugates of an active substance and hydroxyalkyl starch (HAS) are provided herein. The active substance and the HAS are linked by a chemical moiety having a structure according to formula (I) wherein Y is O or S, and X is SH or (F). The conjugate has a structure according to formula (IV) wherein HAS′ is a residue of HAS or a derivative thereof linked to the thioester group, and AS′ is a residue of the active substance or derivative thereof linked to the alpha-X beta-amino group; or a structure according to formula (V) wherein HAS′ is a residue of HAS or derivative thereof linked to the alpha-X beta-amino group, and AS′ is a residue of the active substance or derivative thereof linked to the thioester group, and wherein the group —(C═Y) is derived from the thioester group —(C═Y)—S—R′ and the group HN—CH—CH | 02-23-2012 |
| 20120046236 | TREATMENT OF TRISTETRAPROLINE (TTP) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TTP - The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Tristetraproline (TTP), in particular, by targeting natural antisense polynucleotides of Tristetraproline (TTP). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of TTP. | 02-23-2012 |
| 20120058955 | USE OF DECORINE FOR INCREASING MUSCLE MASS - The invention concerns decorin for increasing muscle mass, particularly in the treatment of muscular dystrophies. | 03-08-2012 |
| 20120065149 | Vitamin receptor binding drug delivery conjugates - The invention describes a vitamin receptor binding drug delivery conjugate, and preparations therefor. The drug delivery conjugate consists of a vitamin receptor binding moiety, a bivalent linker (L), and a drug. The vitamin receptor binding moiety includes vitamins, and vitamin receptor binding analogs and derivatives thereof, and the drug includes analogs and derivatives thereof. The vitamin receptor binding moiety is covalently linked to the bivalent linker, and the drug, or the analog or the derivative thereof, is covalently linked to the bivalent linker, wherein the bivalent linker (L) includes components such as spacer linkers, releasable linkers, and heteroatom linkers, and combinations thereof. Methods and pharmaceutical compositions for eliminating pathogenic cell populations using the drug delivery conjugate are also described. | 03-15-2012 |
| 20120094933 | DERIVATIVES OF APF AND METHODS OF USE - Derivatives of bladder epithelial antiproliferative factor and methods of using them are disclosed. In specific embodiments, the glycopeptide compositions are useful for the treatment and/or prevention of medical conditions, including cancer. In other embodiments, there are compositions and methods related to treatment of bladder conditions. In particular embodiments, the glycopeptide comprises D-pipecolic acid or L-pipecolic acid. | 04-19-2012 |
| 20120094934 | TREATMENT OF TUMOR NECROSIS FACTOR RECEPTOR 2 (TNFR2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TNFR2 - The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Tumor Necrosis Factor Receptor 2 (TNFR2), in particular, by targeting natural antisense polynucleotides of Tumor Necrosis Factor Receptor 2 (TNFR2). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of TNFR2. | 04-19-2012 |
| 20120115795 | Regulation of Sodium Channels by PLUNC Proteins - The present invention relates to the ability of PLUNC proteins, such as SPLUNC1 and SPLUNC2, to bind to sodium channels and inhibit activation of the sodium channels. The invention further relates to methods for regulating of sodium absorption and fluid volume and treating disorders responsive to modulating sodium absorption by modulating the binding of PLUNC proteins to sodium channels. | 05-10-2012 |
| 20120122800 | Long-Acting DNA Dendrimers and Methods Thereof - This invention provides a unique composition which includes a DNA dendrimer combined with siRNA molecule. Further, methods of preparing a composition which includes a DNA dendrimer combined with a siRNA molecule, methods of protecting a DNA dendrimer siRNA complex against degradation in body fluids, methods of protecting a DNA dendrimer against degradation in bodily fluids, and methods of delivering a DNA dendrimer into bodily fluids are provided. | 05-17-2012 |
| 20120122801 | Mannose-6-phosphate receptor mediated gene transfer into muscle cells - The invention relates to glycoside-compound conjugates for use in antisense strategies and/or gene therapy. The conjugates comprise a glycoside linked to a compound, in which the glycoside is a ligand capable of binding to a mannose-6-phosphate receptor of a muscle cell. For example the cells are muscle cells of a Duchenne Muscular Dystrophy (DMD) patient and the conjugate comprises an antisense oligonucleotide which causes ex on skipping and induces or restores the synthesis of dystrophin or variants thereof. | 05-17-2012 |
| 20120135941 | TREATMENT OF 'C TERMINUS OF HSP70-INTERACTING PROTEIN' (CHIP) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO CHIP - The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of ‘C terminus of HSP70-Interacting Protein’ (CHIP), in particular, by targeting natural antisense polynucleotides of ‘C terminus of HSP70-Interacting Protein’ (CHIP). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of CHIP. | 05-31-2012 |
| 20120142610 | TREATMENT OF 'IQ MOTIF CONTAINING GTPASE ACTIVATING PROTEIN' (IQGAP) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO IQGAP - The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of ‘IQ motif containing GTPase activating protein’ (IQGAP), in particular, by targeting natural antisense polynucleotides of ‘IQ motif containing GTPase activating protein’ (IQGAP). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of IQGAP. | 06-07-2012 |
| 20120157391 | PROTEOGLYCAN-CONTAINING MATERIAL - The present invention was made in view of an object to produce a novel proteoglycan-containing material, and find a novel use and/or a superior effect of the proteoglycan-containing material. The present invention provides a proteoglycan-containing material obtained from fish cartilage, wherein the proteoglycan-containing material comprises an acidic saccharide component having a molecular weight of not less than 2000 kDa. The proteoglycan-containing material provides advantageous effects for skin-moisturizing and skin anti-aging, including a superior skin fibroblast proliferation effect, an effect of enhancing and improving the skin barrier function, an effect of enhancing and improving the skin's capability to produce collagen, a dermis-thickening inhibition effect, and the like. | 06-21-2012 |
| 20120178702 | STABLE LIPID-COMPRISING DRUG DELIVERY COMPLEXES AND METHODS FOR THEIR PRODUCTION - Novel stable, concentrated, biologically active and ready-to-use lipid-comprising drug delivery complexes and methods for their production are described. The biological activity of the complexes produced are comparable to the formulations prepared according to the prior art admixture method and upon purification, the complexes produced by the method of this invention are 50 to 500 fold more concentrated than the complexes formed by admixture. The method described herein provides for the large scale production of lipid-comprising drug delivery systems useful for gene therapy and other applications. | 07-12-2012 |
| 20120184497 | DALBAVANCIN COMPOSITIONS FOR TREATMENT OF BACTERIAL INFECTIONS - The invention provides dosage forms and compositions for treatment of bacterial infections. The dosage form may include a sterile, stable, particle-free dalbavancin powder suitable for reconstitution with a pharmaceutically acceptable vehicle. The dosage form may include a dalbavancin factor B | 07-19-2012 |
| 20120196810 | ANIONIC POLYMER, POLYION COMPLEX AND TERNARY POLYMER COMPOSITE USING ANIONIC POLYMER, AND PHARMACEUTICAL COMPOSITION - There are provided an anionic polymer, a polyion complex, and a ternary polymer composite, each of which is stable in a biological environment and is capable of realizing small RNA delivery without causing any undesired immune response. An anionic polymer according to an embodiment of the invention includes: a main chain which includes repeating units having carboxyl groups; and a side chain which is linked with part of the carboxyl groups in the main chain and is represented by the following formula: | 08-02-2012 |
| 20120202752 | Antisense Oligonucleotides - Embodiments of the present invention are directed generally to antisense compounds and compositions for the treatment of muscular dystrophy, and in particular, Duchenne muscular dystrophy (DMD). In one embodiment, the invention is directed to antisense oligonucleotide molecules, pharmaceutical compositions and formulations comprising antisense oligonucleotide molecules, and methods of treating muscular dystrophy related diseases and disorders wherein the antisense oligonucleotide molecules comprises a base sequence selected from the group consisting of SEQ ID NO: 5-8, 10, 12, 14, 16, 24, 27, 28, 34, 35, 37, 40, 42, 44-46, 79, 97, 100, 101, and 116, and combinations thereof. | 08-09-2012 |
| 20120202753 | INHIBITING INFLAMMATION WITH MILK OLIGOSACCHARIDES - A method of inhibiting inflammation in a subject comprising the administration of milk oligosaccharides or glycoconjugates containing milk oligosaccharides is disclosed. | 08-09-2012 |
| 20120208771 | SYNTHETIC CHOLESTERYLAMINE-LINKER DERIVATIVES FOR AGENT DELIVERY INTO CELLS - Synthetic cholesterylamine-linkers can include derivatives of cholesterol, cholesteryl, or sitosteryl coupled through the linker to an agent for delivery into cells. The cholesterylamines are thought to mimic cholesterol in the capacity and mechanism for enhanced entry into cells. The configuration of the cholesterylamine-linker that is thought to provide for enhanced entry into cells includes a cholesterylamine that is coupled to a linker from the amine, and which linker includes a negative charge at a spatial distance from the amine of the cholesterylamine. | 08-16-2012 |
| 20120214747 | RECOMBINANT HUMAN ALPHA1- ANTITRYPSIN - The present invention relates recombinant human α1-antitrypsin (rhAAT) comprising N-linked glycans, wherein at least 10% of said N-linked glycans are tetra-antennary glycans; and the degree of capping with sialic acid on said N-linked glycans (Z/A) is at least 50%. The invention further relates to rhAAT for use as a medicament, in particular for use in the prevention and/or treatment of a disease associated with AAT deficiency, and/or a disease involving neutrophil-mediated tissue damage. | 08-23-2012 |
| 20120232020 | METHOD OF IMPROVING TRANSPLANT FUNCTION USING SOLUBLE COMPLEMENT RECEPTOR TYPE I (sCR1) - A method is disclosed for inhibiting complement activation in brain-dead organ donors, particularly kidney donors, which leads to improvement of organ function of transplanted organs in recipients. The method involves administration of a complement inhibitory protein, specifically a soluble complement receptor type I (sCR1) polypeptide to the donor prior to harvesting the organ for transplant. | 09-13-2012 |
| 20120252741 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS - Provided herein are semi-synthetic glycopeptides having antibacterial activity. The semi-synthetic glycopeptides described herein are made by chemical modification of a glycopeptide by hydrolyzing the disaccharide moiety of the amino acid-4 of the parent glycopeptide in acidic medium to give the amino acid-4 monosaccharide; conversion of the monosaccharide to the amino-sugar derivative; acylation of the amino substituent on the amino acid-4 amino-substituted sugar moiety with certain acyl groups; conversion of the amide group in amino acid-3 to various acylamide, acylsulfonamide, acylsulfonylurea derivatives; aminomethylation with substituent containing sulfonamide or acylsulfonamide group on amino acid-7 through Mannich reaction; and conversion of the acid moiety on the macrocyclic ring to certain substituted amides. Also provided herein are pharmaceutical compositions comprising the semi-synthetic glycopeptides, and methods of use of the semi-synthetic glycopeptides for the treatment and/or prophylaxis of diseases, especially bacterial infections. | 10-04-2012 |
| 20120252742 | Human Single-Chain T Cell Receptors - A soluble human single-chain T cell receptor (TCR) having the structure: Vα2-L-Vβ or Vβ-L-Vα2, wherein L is a linker peptide that links Vβ with Vα, Vβ is a TCR variable β region, and Vα2 is a TCR variable α region of the family 2 is provided. The provided scTCR is useful for many purposes, including the treatment of cancer, viral diseases and autoimmune diseases. | 10-04-2012 |
| 20120277165 | METHODS OF MODULATING FUCOSYLATION OF GLYCOPROTEINS - The present invention provides methods and materials useful for monitoring and regulating the glycosylation of glycoproteins that are recombinantly produced from cells. In particular, methods are provided for monitoring and regulating levels of cellular indicators which affect the level of fucosylation produced by cells. | 11-01-2012 |
| 20120283195 | GLYCOPEPTIDE PHOSPHONATE DERIVATIVES - Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents. | 11-08-2012 |
| 20120302512 | ISOLATED LAMININ-421 - The present disclosure provides isolated laminin-421, methods for making recombinant laminin-421, and host cells that express recombinant laminin-421. The present disclosure also provides nucleic acid sequences encoding full length human laminin β2 chain, expression vectors and host cells thereof. | 11-29-2012 |
| 20120302513 | Mitochondrial Function Improver - Provided are a mitochondrial function improver, an energy consumption promoter, and a lipid combustion promoter which contain a fat globule membrane component as an active ingredient. | 11-29-2012 |
| 20120329727 | TREATMENT OF UNCOUPLING PROTEIN 2 (UCP2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO UCP2 - The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Uncoupling Protein 2 (UCP2), in particular, by targeting natural antisense polynucleotides of Uncoupling Protein 2 (UCP2). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of UCP2. | 12-27-2012 |
| 20130023484 | PERIPHERIN-SPECIFIC AUTOANTIBODIES AS A MARKER FOR NEUROLOGICAL AND ENDOCRINOLOGICAL DISEASE - The present invention provides for methods and materials for detecting a peripherin-specific autoantibody, which can be associated with neurological and endocrinological disease. | 01-24-2013 |
| 20130040897 | GLYCOSYLATION OF PROTEINS IN HOST CELLS - The invention provides means and methods for an improved production of glycosylated recombinant proteins in lower eukaryotes, specifically the production of human-like complex or hybrid glycosylated proteins in yeast. The invention provides genetically modified eukaryotic host cells capable of producing glycosylation optimized proteins useful as immunoglobulins and other therapeutic proteins, and provides cells capable of producing glycoproteins having glycan structures similar to glycoproteins produced in human cell. The invention further provides proteins with human-like glycan structures and novel compositions thereof producible by these modified cells. | 02-14-2013 |
| 20130065838 | SAP VARIANTS AND THEIR USE - Polypeptides are susceptible to denaturation or enzymatic degradation in the blood, liver or kidney. Due to the low stability of some polypeptides, it has been required to administer polypeptide drugs in a sustained frequency to a subject in order to maintain an effective plasma concentration of the active substance. Furthermore, pharmaceutical compositions of therapeutic peptides preferably have a shelf-life of several years in order to be suitable for common use. However, peptide compositions are inherently unstable due to sensitivity towards chemical and physical degradation. In part, the invention provides SAP variant proteins, compositions, pharmaceutical preparations and formulations having a prolonged in vivo half-life, prolonged shelf-life, or rather increased in vitro stability, or increased manufacturing efficiency compared to human SAP. Advantages of increased plasma half-life include, but are not limited to, reducing the amount and/or frequency of dosing. | 03-14-2013 |
| 20130079291 | SIALIC ACID (A-(2-6))-D-AMINOPYRANOSE DERIVATIVES, SYNTHESIS METHODS AND USES THEREOF - N-acyl modified sialic acid (α-(2→6))-D-aminopyranose derivatives, their synthesis methods and uses are disclosed. Sialic acid (α-(2→6))-D-aminopyranose derivatives represented by formula 1 are synthesized by using D-aminogalactose (glucose) and sialic acid as raw materials, which are coupled with carrier proteins or polypeptides to obtain glycoprotein (glycopeptide) conjugates. Acetyl is replaced by derivative acyl in the structures of said compounds, therefore the compounds show good activity in antitumor vaccines. | 03-28-2013 |
| 20130085111 | PRODUCTION OF HUMAN C1 INHIBITOR IN HUMAN CELLS - Vector constructs comprising the coding sequence for human C1 inhibitor are described. Expression of glycosylated recombinant human C1 inhibitor is achieved human cells in high yields. | 04-04-2013 |
| 20130085112 | TREATMENT OF ATONAL HOMOLOG 1 (ATOH1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO ATOH1 - The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Atonal homolog 1 (ATOH1), in particular, by targeting natural antisense polynucleotides of Atonal homolog 1 (ATOH1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of ATOH1. | 04-04-2013 |
| 20130096070 | PEPTIDE TARGETING OF INNER EAR CELLS - Peptide targeting moieties that target the cells of the inner ear can be used for targeted therapeutics. As such, nucleic acids and/or drugs can be associated with the targeting moieties in order to provide therapeutics that are delivered to specific cells in the inner ear. Conjugation of drugs or gene therapy vectors to cell specific peptides may allow the treatment of individual cell types within the inner ear. The peptide targeting moieties can be polypeptides having the sequences of Table 1 in an unnatural configuration. The polynucleotide can either consist of the sequence or include additional polypeptides attached to the ends of the sequences shown in Table 1. The polynucleotide can be in a non-native configuration. For example, the polypeptide is selected from the following: a-h-p-h-h-s-m (SEQ ID NO: 12); h-p-h-h-r-i-f (SEQ ID NO: 29); t-v-p-q-l-t-t (SEQ ID NO: 1); s-t-t-k-l-a-l (SEQ ID NO: 2); m-e-g-y-i-h-r (SEQ ID NO: 3); h-a-i-y-p-r-h (SEQ ID NO: 5); h-s-r-l-l-d-q (SEQ ID NO: 6); i-q-s-p-h-f-f (SEQ ID NO: 7); or y-a-a-h-r-s-h (SEQ ID NO: 8). | 04-18-2013 |
| 20130102545 | TEMPERATURE DEPENDENT ACTIVATION OF CATALYTIC NUCLEIC ACIDS FOR CONTROLLED ACTIVE SUBSTANCE RELEASE - The present invention relates to an active substance release system containing two compounds. The first compound comprises a nanoparticle, combined with an oligonucleotide inhibition strand that is hybridized with a catalytically active nucleic acid. The second compound comprises a carrier, combined with a substrate molecule that is coupled to a therapeutic active substance. By means of external stimulation, the catalytically active nucleic acid of the first compound is released and specifically binds to the substrate molecule of the second compound. This leads to cleavage of the substrate molecule, whereby the active substance bound thereto is released. | 04-25-2013 |
| 20130102546 | METHODS OF TREATING VASCULAR INFLAMMATORY DISORDERS - Provided are methods of treating or delaying the onset of a vascular inflammatory disease (e.g., acute lung injury) in a subject including administering to the subject a therapeutically effective amount of a nucleic acid containing all or a part of the sequence of mature miR-181b (SEQ ID NO: 1). Also provided are methods of decreasing nuclear factor-R? (NF-R?) signaling in an endothelial cell including administering to the subject a nucleic acid containing all or a part of the sequence of mature miR-181b (SEQ ID NO: 1). | 04-25-2013 |
| 20130116198 | Compositions for Regenerating Defective or Absent Myocardium - Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function. | 05-09-2013 |
| 20130137643 | MATERNAL SIALIC ACID SUPPLEMENTATION - The invention provides methods and compositions for improving fetal and child health and development through nutritional supplementation with, for example, sialic acid. Sialic acid can be provided to a female before, during and/or after pregnancy to improve the health and development of a fetus and/or child. The sialic acid can be in a variety of forms in the supplements. | 05-30-2013 |
| 20130137644 | CELL PENETRATING PEPTIDE CONJUGATES FOR DELIVERING OF NUCLEIC ACIDS INTO A CELL - The invention provides cell penetrating peptide-nucleic acid conjugates having the formula P-L-N, wherein P is a cell penetrating peptide, N is a nucleic acid, preferably an oligonucleotide and more preferably a siRNA, and L is a hydrophilic polymer, preferably a polyethylene glycol (PEG)-based linker linking P and N together. Compositions, methods of use and methods for producing such conjugates are also disclosed. | 05-30-2013 |
| 20130172269 | LYOPHILIZED RECOMBINANT VWF FORMULATIONS - The present invention provides long-term stable pharmaceutical formulations of lyophilized recombinant von-Willebrand Factor (rVWF) and methods for making and administering said formulations. | 07-04-2013 |
| 20130190253 | Glycosylation of Molecules - Described herein are methods and genetically engineered cells useful for producing an altered N-glycosylation form of a target molecule. Also described are methods and molecules with altered N-glycosylation useful for treating a variety of disorders such as metabolic disorders. | 07-25-2013 |
| 20130196930 | POLYNUCLEOTIDES ENCODING RECOMBINANT LUBRICIN MOLECULES AND USES THEREOF - Recombinant lubricin molecules and uses thereof. Novel recombinant lubricin molecules and their uses as lubricants, anti-adhesive agents and/or intra-articular supplements for, e.g., synovial joints, meniscus, tendon, peritoneum, pericardium and pleura, are provided. | 08-01-2013 |
| 20130244953 | DUAL SECURED THERAPEUTIC PEPTIDE DELIVERY SYSTEM - A delivery system is described that includes a polymer network that can incorporate a therapeutic peptide for targeted delivery to a cell, e.g., a cancer cell. The polymer network can secure the therapeutic peptide via two different mechanisms. First, a polymer of the network can interact with the therapeutic peptide via charge/charge interaction to form a complex with the peptide, thereby holding the peptide within the network. Second, the polymer network can be crosslinked, providing another level of securement for holding the therapeutic peptide within the network. The two levels of securement can be reversible, and following delivery of the network to the interior of a targeted cell reversal of the securement mechanisms can release the therapeutic peptide within the cell. | 09-19-2013 |
| 20130261065 | TREATMENT OF NANOG RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO NANOG - The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of NANOG, in particular, by targeting natural antisense polynucleotides of NANOG. The invention also related to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of NANOG. | 10-03-2013 |
| 20130267473 | MANNOSIDASES CAPABLE OF UNCAPPING MANNOSE-1-PHOSPHO-6-MANNOSE LINKAGES AND DEMANNOSYLATING PHOSPHORYLATED N-GLYCANS AND METHODS OF FACILITATING MAMMALIAN CELLULAR UPTAKE OF GLYCOPROTEINS - The invention provides mannosidases capable of uncapping mannose-1-phospho-6-mannose moieties and demannosylating phosphorylated N-glycans, methods of using such mannosidases, glycoproteins produced using the methods, as well as methods of facilitating mammalian cellular uptake of glycoproteins. | 10-10-2013 |
| 20130274204 | Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders - The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition including Crohn's disease and ulcerative colitis, and cancer. | 10-17-2013 |
| 20130281382 | STABLE LIPID-COMPRISING DRUG DELIVERY COMPLEXES AND METHODS FOR THEIR PRODUCTION - Novel stable, concentrated, biologically active and ready-to-use lipid-comprising drug delivery complexes and methods for their production are described. The biological activity of the complexes produced are comparable to the formulations prepared according to the prior art admixture method and upon purification, the complexes produced by the method of this invention are 50 to 500 fold more concentrated than the complexes formed by admixture. The method described herein provides for the large scale production of lipid-comprising drug delivery systems useful for gene therapy and other applications. | 10-24-2013 |
| 20130288986 | POLYMER DRUG CONJUGATES WITH TETHER GROUPS FOR CONTROLLED DRUG DELIVERY - Described herein is a cyclodextrin containing polymer conjugate. | 10-31-2013 |
| 20130345151 | PREPARATION FOR ORAL ADMINISTRATION COMPRISES QUERCETIN GLYCOSIDE AND A WATER BASED SOLVENT EXTRACT OF CARTILAGE CONTAINING CHONDROITIN SULFATE - It is an object of the present invention to provide a preparation for oral administration in which the bitter taste derived from quercetin glycoside is improved. | 12-26-2013 |
| 20140024604 | GLYCOPEPTIDE PHOSPHONATE DERIVATIVES - Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents. | 01-23-2014 |
| 20140038906 | THERAPEUTIC AND DIAGNOSTIC METHODS INVOLVING BIGLYCAN AND UTROPHIN - The present disclosure provides methods for predicting a patient's response to biglycan therapy for diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, for example, due to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of such diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders. This application also provides combination therapeutics, such as a biglycan therapeutic and a utrophin therapeutic. | 02-06-2014 |
| 20140057856 | Compositions and Methods For Enhancing Sialic Acid Levels In Tissue - The invention relates to compositions and methods for increasing sialic acid uptake and/or incorporation into tissue following gastrointestinal ingestion of compositions that contain sialic acid. | 02-27-2014 |
| 20140080766 | COMPOSITIONS AND METHODS FOR MACROMOLECULAR DRUG DELIVERY - The present invention features compositions and methods for delivering a therapeutic agent to the cytoplasm of a cell. We have developed, inter alia, a system in which two or more distinct moieties—at least one therapeutic moiety and at least one potentiating moiety—selectively target and specifically bind cell surface molecules that are then internalized to an intracellular, membrane-bound compartment, such as an endosome. In some embodiments, as discussed further below, a third moiety that induces clustering of the targeted cell surface molecule can also be employed. Regardless of whether the compositions and methods include two or three moieties, the therapeutic agent can be any agent one wishes to deliver to the cytoplasm of a cell, and the potentiating agent can be any agent that destabilizes the intracellular, sub-cellular compartment in which the therapeutic agent is sequestered. The potentiating moiety can include, for example, a lytic agent (i.e., an agent that lyses or otherwise increases the permeability of the membrane of the intracellular compartment containing the therapeutic agent). To direct the various moieties of the system, including the therapeutic, potentiating, and clustering moieties, to a selected cellular target, any of the moieties can include a binding agent that selectively targets and specifically binds a molecule present on the surface of the targeted cell. | 03-20-2014 |
| 20140080767 | MATERNAL SIALIC ACID SUPPLEMENTATION - The invention provides methods and compositions for improving fetal and child health and development through nutritional supplementation with, for example, sialic acid. Sialic acid can be provided to a female before, during and/or after pregnancy to improve the health and development of a fetus and/or child. The sialic acid can be in a variety of forms in the supplements. | 03-20-2014 |
| 20140142047 | POST PROTEIN HYDROLYSIS REMOVAL OF A POTENT RIBONUCLEASE INHIBITOR AND THE ENZYMATIC CAPTURE OF DNA - The present invention concerns compositions and methods of extracting infectious pathogens from a volume of blood. In one embodiment, the method includes the steps of creating a fibrin aggregate confining the pathogens and introducing a fibrin lysis reagent to expose the pathogens for analysis. The present invention also concerns materials and methods for removing aurintricarboxylic acid (ATA) from a sample. | 05-22-2014 |
| 20140162961 | COMPOSITIONS AND METHODS FOR TRANSPORT ACROSS THE BLOOD BRAIN BARRIER - Compositions and methods are provided including a transporter peptide derived from the loop2 domain of the neuronally-derived lynx1 protein which can be conjugated to an effector agent to form a transporter-effector complex for transport of the therapeutic effector agent to a target that is found across the blood brain barrier. | 06-12-2014 |
| 20140162962 | NOVEL LIPIDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS - The present invention provides novel amino-lipids, compositions comprising such amino-lipids and methods of producing them. In addition, lipid nanoparticles comprising the novel amino-lipids and a biologically active compound are provided, as well as methods of production and their use for intracellular drug delivery. | 06-12-2014 |
| 20140187499 | SUBSTITUTED ANIONIC COMPOUNDS CONSISTING OF A BACKBONE MADE UP OF A DISCRETE NUMBER OF SACCHARIDE UNITS - The invention relates to substituted anionic compounds consisting of a backbone made up of a discrete number u of between 1 and 8 (1≦u≦8) of identical or different saccharide units, linked via identical or different glycosidic bonds, said saccharide units being chosen from the group consisting of pentoses, hexoses, uronic acids, N-acetylhexosamines in cyclic form or in open reduced form, which are randomly substituted. It also relates to the process for the preparation thereof and to the pharmaceutical compositions comprising same. | 07-03-2014 |
| 20140206627 | KISSPEPTIDE-PENTASACCHARIDE CONJUGATES - The invention relates to kisspeptide-pentasaccharide conjugates having the general formula (I) wherein Z | 07-24-2014 |
| 20140274911 | METHODS OF CELL CULTURE - Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using ammonium and/or lysine, are described. | 09-18-2014 |
| 20140274912 | METHODS OF CELL CULTURE - Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using putrescine, are described. | 09-18-2014 |
| 20140274913 | METHODS FOR TREATING INFLAMMATION, AUTOIMMUNE DISORDERS AND PAIN - Compositions and methods for treating, reducing, or preventing a disease or symptom such as gingivitis, periodontitis, gastritis, colitis, ileitis, Crohn's disease, chronic inflammatory intestinal disease, inflammatory bowel syndrome, chronic inflammatory bowel disease, celiac disease, ulcerative colitis, a gastric ulcer, a peptic ulcer, a buccal ulcer, a nasopharyngeal ulcer, an esophageal ulcer, a duodenal ulcer, a gastrointestinal ulcer, an autoimmune disorder, or pain. The method includes identifying a patient in need of treatment and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Kits comprising such compositions and instructions on such methods are also contemplated herein. | 09-18-2014 |
| 20140309176 | ETHANOL DEPENDENCE OF ALPHA1 ANTITRYPSIN C-TERMINAL LYS TRUNCATION BY BASIC CARBOXYPEPTIDASES - The present invention provides methods of preparing alpha-1-antiproteinase inhibitor and controlling the amount of des-lys alpha-1-antiproteinase inhibitor in the preparation, and compositions comprising the same, as well as methods of treatment using the same. | 10-16-2014 |
| 20140315828 | CROSS-LINKED SILK-HYALURONIC ACID COMPOSITIONS - Compositions useful as dermal fillers and methods using such compositions to treat various skin and soft tissue conditions. The dermal fillers can comprise silk attached to hyaluronic acid using for example two cross linkers and can be used to treat of facial imperfections, facial defects, facial augmentations, breast imperfections, breast augmentations or breast reconstructions. | 10-23-2014 |
| 20140315829 | Compositions And Methods For Enhancing Sialic Acid Levels In Tissue - The invention relates to compositions and methods for increasing sialic acid uptake and/or incorporation into tissue following gastrointestinal ingestion of compositions that contain sialic acid. | 10-23-2014 |
| 20140329762 | COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY - Improved compositions and methods for treating muscular dystrophy by administering antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping are described. | 11-06-2014 |
| 20140329763 | ANTI-INFLUENZA NUCLEIC ACID, PEPTIDE NUCLEIC ACID AND PREPARATIONS THEREOF - Disclosed are an anti-influenza nucleic acid, peptide nucleic acid and preparations thereof. The nucleic acid of the invention consists of any one or several of SEQ ID NOs: 1-12, and any one or several of SEQ ID NOs: 13-24. The peptide nucleic acid of the invention consists of any one or several of SEQ ID NOs: 25-36, and any one or several of SEQ ID NOs: 37-48. The peptide nucleic acid preparation of the invention has effective ingredients of said peptide nucleic acids. The anti-influenza peptide nucleic acid of the invention is of high bioavailability and stable physical and chemical properties with no toxic or side effect and no drug tolerance. With low cost, the drugs can inhibit influenza virus replication and have good anti-virus effect. | 11-06-2014 |
| 20140336131 | METHODS FOR TREATING INFLAMMATION, AUTOIMMUNE DISORDERS AND PAIN - Disclosed herein are methods of treating, reducing, or preventing a disease such as oral mucositis, gastric mucositis, or inflammatory fibrosis, comprising identifying a patient in need of treatment and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Kits comprising such compositions and instructions on such methods are also contemplated herein. | 11-13-2014 |
| 20150031630 | Peptide Pharmaceuticals - Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics. | 01-29-2015 |
| 20150080318 | Compositions for the Treatment or Prophylaxis of Viral Infections - A compound of the general formula (III): wherein X is O, S, NH or CH | 03-19-2015 |
| 20150087601 | POLYMER MICELLE COMPLEX INCLUDING NUCLEIC ACID - It is an object of the present invention to provide: a polyion complex that sufficiently retains a photosensitizing substance in serum and is excellent in terms of structural stability; a nucleic acid polyplex as a constituent thereof; and a device and a kit for delivering a nucleic acid into a cell. | 03-26-2015 |
| 20150111834 | RECIPE FOR IN-SITU GEL, AND IMPLANT, DRUG DELIVERY SYSTEM FORMED THEREBY - The disclosure provides a recipe for in-situ gel, formed by dissolving at least one polymer and at least one gel prevention agent in a polar solvent to form a solution and placing the solution in a condition for in-situ forming gels. The disclosure also provides an implant and a drug delivery system formed by the recipe. | 04-23-2015 |
| 20150148301 | INHIBITORS OF THE ACTIVITY OF COMPLEX (III) OF THE MITOCHONDRIAL ELECTRON TRANSPORT CHAIN AND USE THEREOF - The present invention relates to inhibitors of the activity of Complex (III) of the mitochondrial electron transport chain and use thereof in treatment and/or prevention of cancers presenting tumour-initiating cells. The present invention further relates to pharmaceutical compositions containing said inhibitors alone or in combination with other pharmaceutically active agents, and their use as medicaments or as agrochemicals where their properties as inhibitors of the mitochondrial respiration is of benefit. | 05-28-2015 |
| 20150314007 | LINKER-PAYLOAD MOLECULE CONJUGATES - The invention relates to novel linker-payload molecule conjugates. The invention also relates to novel cell binder-linker-payload molecule conjugates, in particular antibody conjugates of dolastatin or auristatin derivatives. | 11-05-2015 |
| 20150337014 | Theragnostic Particles - The present invention provides viral-based nanoparticles for therapeutic and diagnostic use, and methods for making and using the nanoparticles. Specifically, such nanoparticles comprise decoration-competent viral particles shells such as expanded capsids of phages, stabilized with engineered decoration proteins that have been linked to one or more compounds not naturally occurring on a wild type viral capsid. | 11-26-2015 |
| 20150374845 | COMPOUNDS THAT BIND DYSTROGLYCAN AND USES THEREOF - Disclosed herein are methods and compositions involved in identifying cells that lack apico-basal polarity as well as methods and compositions involved in selectively delivering payload molecules to cells that lack apico-basal polarity, and methods of selecting test compounds that restore apico-basal polarity. | 12-31-2015 |
| 20160067315 | INHIBITOR OF EXTRACELLULAR TRAP FORMATION IN LEUKOCYTES - The present invention has an object of providing a novel drug inhibiting formation of leukocyte extracellular traps. The present invention provides a lactoferrin-containing inhibitor of formation of leukocyte extracellular traps, and a lactoferrin-containing composition for treating a disease associated with the formation of the leukocyte extracellular traps. | 03-10-2016 |
| 20160068574 | Modified Proteins and Methods of Use Thereof - This invention is generally related to small proteins, such as miniature proteins, including avian pancreatic polypeptide (aPP), modified so that the small proteins reach the cytosol. In some embodiments, the modified protein molecules deliver an associated cargo molecule to the cytosol. Other embodiments of the invention relate to modified protein fusion molecules that reach the cytosol. | 03-10-2016 |
| 20160184406 | COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION - The present invention relates to a complexed RNA, comprising at least one RNA complexed with one or more oligopeptides, wherein the oligopeptide, which has the function of cell-penetrating peptide (CPP), has a length of 8 to 15 amino acids and has the empirical formula (Arg) | 06-30-2016 |
| 20160184449 | PEPTIDE-AND AMINE-MODIFIED GLUCAN PARTICLES FOR DELIVERY OF THERAPEUTIC CARGOES - The present invention generally relates to peptide-modified glucan particles (PcGPs) and/or amine-modifies glucan particles (amGPs) for use in delivering payload molecules, in particular, nucleic acid payload molecules, to cells. The invention relates to particular peptides and small molecule amines which are ideally suited for use in the pcGPs and amGPs of the invention, respectively. Preferred aspects of the invention feature a single-component delivery vehicle comprising the pcGPs or amGPs and siRNA, for use as an siRNA delivery vehicle. Methods of making such particles and methods of using such particles, for example, for in mediating in vitro and in vivo gene silencing are disclosed herein. | 06-30-2016 |
| 20100292137 | Antibiotics and Methods For Producing Them - The invention relates to cyclic peptides and methods for producing and using them. Provided is amongst others a method for determining whether a compound comprises antibiotic activity, the method comprising providing a cyclic peptide to a bacterium wherein a 23S rRNA in a 5OS ribosomal subunit does not comprises a 2′ O-methylation at a nucleotide that corresponds to nucleotide C 1920 in | 11-18-2010 |
| 20110039764 | THERAPEUTIC COMPOSITION FOR BONE INFECTIOUS DISEASE - A biodegradable composition containing an antibiotic or a physiologically active substance for use in surgical treatment of infection. A highly safe and biocompatible composition showing appropriately sustained release of an antibiotic or physiologically active substance which produces excellent antibiotic and bone regenerating effects. A composition having excellent effects in treatment of bone infection occurring after operations for total arthroplasty and/or bone fracture. (1) A medical composition for treatment of bone infection comprising an antibiotic and a polysaccharide. | 02-17-2011 |
| 20110124551 | FORMULATIONS OF DAPTOMYCIN - Long term storage stable daptomycin-containing compositions are disclosed. The compositions include a pharmacologically acceptable fluid including daptomycin or a pharmaceutically acceptable salt thereof at a concentration of less than or equal to about 25 mg/mL, and a calcium source. The formulations are surprisingly free of degradation products such as the hydrolysis product of daptomycin, the β-isomer of daptomycin and anhydro daptomycin after storage periods of at least about 18 months under refrigerated conditions. | 05-26-2011 |
| 20110144003 | MAINTENANCE THERAPY REGIME/REGIMEN FOR THE TREATMENT OF ACNE - A novel maintenance therapy regime/regimen for the treatment of acne related diseases includes administering an oral antibiotic with a topical fixed-dose combination of a retinoid, such as adapalene, and an anti-bacterial agent, such as benzoyl peroxide. | 06-16-2011 |
| 20110178001 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS - The present invention relates to phosphonated Rifamycins, and methods of making and using such compounds. These compounds are useful as antibiotics for prophylaxis and/or the treatment of bone and joint infections, especially for the prophylaxis and/or treatment of osteomyelitis. | 07-21-2011 |
| 20110178002 | High Affinity Ligands Bind to Clostridium Difficile Toxin A - Glycans are identified which have high affinity for | 07-21-2011 |
| 20110190199 | Combination Therapy for Tuberculosis - The present invention relates to methods of treating tuberculosis, including multi-drug resistant varieties and latent tuberculosis. More particularly, the present invention relates to a method of treating tuberculosis in a mammal comprising administering to said mammal in need thereof an effective amount of a compound of formula (I), (S)—N-[[3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide, or a pharmaceutically acceptable salt thereof in combination with at least two agents useful in the treatment of tuberculosis. The present invention also relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, (ii) a therapeutically effective amount of at least one agent useful in the treatment of tuberculosis and (iii) one or more pharmaceutically acceptable carriers or vehicles. | 08-04-2011 |
| 20110207658 | High Purity Lipopeptides - The invention discloses highly purified daptomycin and to pharmaceutical compositions comprising this compound. The invention discloses a method of purifying daptomycin comprising the sequential steps of anion exchange chromatography, hydrophobic interaction chromatography and anion exchange chromatography. The invention also discloses a method of purifying daptomycin by modified buffer enhanced anion exchange chromatography. The invention also discloses an improved method for producing daptomycin by fermentation of | 08-25-2011 |
| 20110218140 | BIODEGRADABLE THERAPEUTIC NANOPARTICLES CONTAINING AN ANTIMICROBIAL AGENT - Compositions that include antimicrobial agents and biodegradable delivery-vehicles adapted to enter a cell and release the antimicrobial agents in the cell as they biodegrade. Also provided are compositions that include first and second delivery vehicles including first and second antimicrobial agents, wherein the first delivery vehicles are adapted to release the first antimicrobial agents at a rate that differs from that at which the second delivery vehicles release the second antimicrobial agents, articles of manufacture that include one or more biodegradable delivery vehicles, and methods of making and using the compositions to treat intracellular and/or extracellular infections are disclosed. | 09-08-2011 |
| 20110224129 | Lipopeptide Compounds and Their Use - The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain lipopeptide compounds comprising a cyclic peptide bearing a lipid side chain (for convenience, collectively referred to herein as “LP compounds”), which, inter alia, are antimicrobial, particularly antibacterial. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to provide an antimicrobial function, particularly an antibacterial function, and in the treatment of diseases and conditions that are mediated by microbes, particularly bacteria, that are ameliorated by the antimicrobial function, particularly an antibacterial function, including bacterial diseases, optionally in combination with another agent, for example, another antibacterial agent. | 09-15-2011 |
| 20110257079 | Parenteral Combination Therapy for Infective Conditions With Drug Resistant Bacterium - The invention describes a pharmaceutical composition to combat multiple-drug-resistant bacteria in non-ocular infective conditions. Compositions comprising glycopeptides, in particular vancomycin, and cephalosporins, in particular ceftriaxone, are disclosed. Such compositions are found to be useful for parenteral administration for hospitalized patients with serious infections. Specifically, this invention also discloses a pharmaceutical composition further including an excipient such as CVMC agent and is available in dry powder form for reconstitution before injection with a suitable solvent. The pharmaceutical compositions of this invention have been found normally to enhance resistance to precipitation in solutions to be administered parenterally. The invention also gives details of the dosage forms stored in sealed containers to be reconstituted before use. The invention further provides a process to manufacture these compositions and also a method of treating a subject having non-ocular infective conditions due to multi drug resistant bacterium. | 10-20-2011 |
| 20110294725 | Use of predissolved pristinamycin-type and polyether ionophore type antimicrobial agents in the production of ethanol - A method of controlling microorganisms such as | 12-01-2011 |
| 20110294726 | ANTIBIOTIC THERAPY TO REDUCE THE LIKELIHOOD OF DEVELOPING POST-INFECTIOUS IRRITABLE BOWEL SYNDROME - The present invention provides for methods of preventing IBS, preventing long term irregular bowel pattern, reducing the likelihood of developing or having IBS, reducing the likelihood of developing or having long term irregular bowel pattern, mitigating IBS, mitigating long term irregular bowel pattern and reducing the likelihood of developing non-ulcer dyspepsia. The methods comprise providing an antibiotic and administering the antibiotic to a subject in need thereof. | 12-01-2011 |
| 20120035097 | METHODS OF TREATING BACTERIAL INFECTIONS USING ORITAVANCIN - The present invention is directed to methods of treating a bacterial infection in a subject through the administration of a therapeutically effective amount of a glycopeptide antibiotic to a subject having a bacterial infection. The effective amount of the glycopeptide antibiotic that is administered to the subject provides a fraction of the glycopeptide antibiotic administered to the subject bound to serum proteins within the subject and within a selected range. | 02-09-2012 |
| 20120129763 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS - Semi-synthetic glycopeptides having antibacterial activity are described, in particular, the semi-synthetic glycopeptides described herein are made by chemical modification of a glycopeptide (Compound A, Compound B, Compound H or Compound C) or monosaccharide made by hydrolyzing the disaccharide moiety of the amino acid-4 of the parent glycopeptide in acidic medium to give the amino acid-4 monosaccharide; conversion of the monosaccharide to the amino-sugar derivative; acylation of the amino substituent on the amino acid-4 amino-substituted sugar moiety on these scaffolds with certain acyl groups; and conversion of the acid moiety on the macrocyclic ring of these scaffolds to certain substituted amides. Key reaction is the treatment of properly protected intermediate compound with isocyanate or carrying a Hofmann degradation of the primary amide of the 3 | 05-24-2012 |
| 20120157375 | Identification of Inhibitors of a Bacterial Stress Response - A system, a composition, a method and a kit for identifying anti-bacterial agents are provided. The invention described herein is useful in identifying inhibitors of any bacterial stress response. Moreover, the invention can be applied to any sRNA and its target, any transcription factor and its target, and any transcription factor/sRNA pair (i.e., a transcription factor that regulates a sRNA). In particular, the present invention provides a system, a composition, a method and a kit for the identification of cyclic peptides that block the σ | 06-21-2012 |
| 20120202737 | New bacitracin antibiotics - The invention concerns new Bacitracin compounds containing methylene-isoleucine. | 08-09-2012 |
| 20120277145 | Compounds - The present invention pertains generally to certain compounds of the deoxyactagardine A and B type. Such compounds are suitable for use in the treatment of microbial infections, for example | 11-01-2012 |
| 20120316106 | SYNERGISTIC ANTIBIOTIC COMBINATIONS AND DERIVATIVES - Improved antibiotic analogs, and synergistic combinations of antibiotics designed based on structural crystallographic analysis, are provided as well as pharmaceutical compositions that include these improved analogs and synergistic combinations, along with methods for their production and use. The synergistic combinations target neighboring sites in the ribosome demonstrating the importance of the corresponding ribosomal sites for development of clinically-relevant synergistic antibiotics. | 12-13-2012 |
| 20130005647 | MUTANT NISIN SER 29 DERIVATIVES AND THE USE THEREOF - A Nisin derivative or variant, comprising an amino acid substitution at amino acid position 29 in the amino acid sequence. The Nisin derivative exhibits enhanced antimicrobial activity when compared to wild type Nisin. The Nisin derivative has an application as a natural food additive and as a therapeutic agent. | 01-03-2013 |
| 20130059774 | EFFLUX PUMP INHIBITORS - Novel compositions and methods of reducing microbial resistance to antimicrobial agents and treating infections are disclosed. In particular, compositions and methods of inhibiting efflux pump activity, treating infection and methods of enhancing antimicrobial activity of antimicrobial agents are provided. | 03-07-2013 |
| 20130059775 | Nucleic Acid Complexes - The present invention relates to complexes of transcription factor decoys, their delivery to bacteria and their formulation. In particular, the present invention resides in an antibacterial complex comprising a nucleic acid sequence and one or more delivery moieties selected from quaternary amine compounds; bis-aminoalkanes and unsaturated derivatives thereof, wherein the amino component of the aminoalkane is an amino group forming part of a heterocyclic ring; and an antibacterial peptide. | 03-07-2013 |
| 20130096052 | PROCALCITONIN FOR THE DIAGNOSIS OF BACTERIAL INFECTIONS AND GUIDANCE OF ANTIBIOTIC TREATMENT IN PATIENTS WITH NON-SPECIFIC COMPLAINTS - The present invention relates to the determination of the level of marker peptides in a sample derived from a bodily fluid of a subject presenting with non-specific complaints. | 04-18-2013 |
| 20130109617 | SUBSTITUTED TETRACYCLINE COMPOUNDS FOR TREATMENT OF BACILLUS ANTHRACIS INFECTIONS | 05-02-2013 |
| 20130217620 | IONIC SILICONE HYDROGELS - The present invention relates to ionic silicone hydrogel contact lenses which comprise at least one pharmaceutical or nutriceutical component and are formed from reaction mixtures comprising a mixture of slow-reacting hydrophilic monomers, including at least one slow-reacting ionic monomer, at least one silicone-containing component and at least one hydroxyl-containing component, wherein the ratio of the slow-reacting hydrophilic component half lives to the silicone-containing component half life is at least 2. | 08-22-2013 |
| 20130252883 | Macrocycles and Their Uses - The present application describes a method of treating a bacterial infection comprising administering to a subject in need thereof a pharmaceutically acceptable amount of a defined macrocycle compound. | 09-26-2013 |
| 20130288955 | STRUCTURAL AND MECHANISTIC BASIS FOR NOVEL COMPOUND BIOSYNTHESIS USING 4-ELECTRON HEXOSE OXIDASE - A novel pharmaceutical composition comprising a compound of formula (I) is disclosed. The novel compound can include a pharmaceutically acceptable carrier. The invention further comprises methods for making compounds of formula (I) using Dbv29, and to the use of compound of formula (I) to treat bacterial infections. | 10-31-2013 |
| 20130296228 | EFFLUX PUMP INHIBITORS - Novel compositions and methods of reducing microbial resistance to antimicrobial agents and treating infections are disclosed. In particular, compositions and methods of inhibiting efflux pump activity, treating infection and methods of enhancing antimicrobial activity of antimicrobial agents are provided. | 11-07-2013 |
| 20130338059 | Methods for Differentiating Between Disease States - This disclosure relates to methods for differentiating between mammals having active and latent Tuberculosis disease, by determining the percentage of polyfunctional CD4+ T-cells expressing TNF-alpha, IFN-gamma, and IL-2, or by determining expression of IL-17. | 12-19-2013 |
| 20140024577 | METHODS FOR PREPARING PURIFIED LIPOPEPTIDES - The present invention relates to crystalline and crystal-like forms of lipopeptides, including daptomycin, a lipopeptide antibiotic with potent bactericidal activity against gram-positive bacteria, including strains that are resistant to conventional antibiotics. The present invention relates to methods of purifying lipopeptides, including daptomycin, a lipopeptide antibiotic with potent bactericidal activity against gram-positive bacteria, including strains that are resistant to conventional antibiotics. The present invention also relates to pharmaceutical compositions comprising the purified form of the lipopeptide and methods of using these compositions. | 01-23-2014 |
| 20140066364 | CYANOACRYLATE TISSUE ADHESIVES - A tissue adhesive including cyanoacrylate and polyethylene glycol (PEG), wherein the PEG remains a polyether and wherein the tissue adhesive is bioabsorbable. A tissue adhesive including cyanoacrylate bulk monomer and cyanoacrylate nanoparticles containing a therapeutic therein. A kit for applying tissue adhesive, including the tissue adhesive described above and an applicator. Methods of accelerating degradation of a cyanoacrylate tissue adhesive applying a tissue adhesive, closing an internal wound, administering a therapeutic to tissue, treating cancer, and preventing infection in a wound. Methods of method of making a bioabsorbable tissue adhesive and making a therapeutic tissue adhesive. | 03-06-2014 |
| 20140066365 | USE OF CALIXARENES ASSOCIATED WITH AN ANTIBIOTIC IN THE TREATMENT OF BACTERIAL INFECTIONS - A product comprising at least one given antibiotic and a calixarene for use as medicament. | 03-06-2014 |
| 20140094402 | Lantibiotic NAI-802, Pharmaceutically Acceptable Salts, Compositions and Uses Thereof - The present invention concerns novel lantibiotic compounds, processes for the isolation and preparation thereof, pharmaceutical compositions containing the same, pharmaceutical acceptable salts thereof, and methods of use of the lantibiotics as antibacterial agents. | 04-03-2014 |
| 20140094403 | ENOPEPTINS, USES THEREOF, AND METHODS OF SYNTHESIS THERETO - Provided herein are inventive enopeptin compounds of Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Further provided are methods of preparation, use, and treatment. | 04-03-2014 |
| 20140100157 | METHOD OF INHIBITING CLOSTRIDIUM DIFFICILE BY ADMINISTRATION OF ORITAVANCIN - Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against both a vegetative form of | 04-10-2014 |
| 20140142031 | CYCLIC PEPTIDE FROM NONOMURAEA SP., PROCESS FOR THE PRODUCTION THEREOF, AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF MYCOBACTERIA RELATED DISEASE COMPRISING THE SAME - The present invention relates to novel anti-TB cyclic peptides from | 05-22-2014 |
| 20140162939 | ANTIBACTERIAL AGENTS: SALINAMIDE DERIVATIVES - The invention provides compounds of formula (I): | 06-12-2014 |
| 20140162940 | BIPARTITE INHIBITORS OF BACTERIAL RNA POLYMERASE: SAL-TARGET-INHIBITOR/NUCLEOSIDE-ANALOG-INHIBITOR CONJUGATES - The invention provides bipartite inhibitors of bacterial RNA polymerase that contain: (i) a first moiety that binds to the salinamide binding site of a bacterial RNA polymerase; (ii) a second moiety comprising a nucleoside analog; and (iii) a linker connecting said first and second moieties. | 06-12-2014 |
| 20140187475 | Lantibiotic Compositions and Methods For Preventing or Treating Mastitis - A composition suitable for application to the skin comprising at least one lantibiotic, an acidic external phase aqueous solution, at least one pharmaceutically acceptable internal phase carrier material, and a combination thereof. A method for preventing or treating mastitis, comprising administering to a human in need of such treatment a topical composition comprising a therapeutically-effective amount of at least one lantibiotic, an acidic aqueous solution, and at least one pharmaceutically acceptable carrier material. | 07-03-2014 |
| 20140206602 | BIPARTITE INHIBITORS OF BACTERIAL RNA POLYMERASE - The invention provides bipartite inhibitors of bacterial RNA polymerase having the general structural formula (I): X-α-Y (I) wherein X is an moiety that binds to the rifamycin binding site of a bacterial RNA polymerase, Y is a moiety that binds to the GE23077 binding site of a bacterial RNA polymerase, and is a linker. The invention also provides compositions comprising such compounds, methods of making such compounds, and methods of using said compounds. The invention has applications in control of bacterial gene expression, control of bacterial growth, antibacterial chemistry, and antibacterial therapy. | 07-24-2014 |
| 20140256616 | MODIFIED GREEN TEA POLYPHENOL FORMULATIONS - Modified green tea polyphenols and methods of their use are provided. One aspect provides compounds and compositions containing green tea polyphenols with one on more ester-linked fatty acids. | 09-11-2014 |
| 20140256617 | In Situ Forming Hydrogel and Method Using Same - A hydrogel (I), comprising a polymer backbone wherein an aqueous solution of the hydrogel comprises a first lower critical solution temperature, and wherein the hydrogel is configured to be converted in vivo into a modified hydrogel, and wherein an aqueous solution of the modified hydrogel comprises a second lower critical solution temperature, and wherein the second lower critical solution temperature is greater than the first lower critical solution temperature. | 09-11-2014 |
| 20140274881 | BIODEGRADABLE THERAPEUTIC NANOPARTICLES CONTAINING AN ANTIMICROBIAL AGENT - Compositions that include antimicrobial agents and biodegradable delivery vehicles adapted to enter a cell and release the antimicrobial agents in the cell as they biodegrades. Also provided are compositions that include first and second delivery vehicles including first and second antimicrobial agents, wherein the first delivery vehicles are adapted to release the first antimicrobial agents at a rate that differs from that at which the second delivery vehicles release the second antimicrobial agents, articles of manufacture that include one or more biodegradable delivery vehicles, and methods of making and using the compositions to treat intracellular and/or extracellular infections are disclosed. | 09-18-2014 |
| 20140296133 | SILA ANALOGS OF OXAZOLIDINONE DERIVATIVES AND SYNTHESIS THEREOF - The invention discloses silaanalogs of oxazolidinone compounds, to pharmaceutical compositions and to the synthesis of the oxazolidinone derivatives of formula I. The invention further relates to methods of treating a subject suffering with gram positive pathogens including those resistant to methicillin and vancomycin using the compound(s) or modulation of coagulation properties of blood-clotting cascade or compositions of the oxazolidinone derivatives of the invention. | 10-02-2014 |
| 20140296134 | METHODS AND USES FOR METABOLIC PROFILING FOR CLOSTRIDIUM DIFFICILE INFECTION - Embodiments include methods for generating a metabolite profile of a stool sample and methods of assessing the status of a subject using the metabolic profile derived from a stool sample. | 10-02-2014 |
| 20140315790 | AMINOTHIAZOLES AND THEIR USES - The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases. | 10-23-2014 |
| 20140371135 | HIGH PURITY LIPOPEPTIDES - The invention discloses highly purified daptomycin and to pharmaceutical compositions comprising this compound. The invention discloses a method of purifying daptomycin comprising the sequential steps of anion exchange chromatography, hydrophobic interaction chromatography and anion exchange chromatography. The invention also discloses a method of purifying daptomycin by modified buffer enhanced anion exchange chromatography. The invention also discloses an improved method for producing daptomycin by fermentation of | 12-18-2014 |
| 20150024996 | PHARMACEUTICAL COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION AND METHODS FOR FABRICATING THEREOF - Pharmaceutical compositions for intraocular injection are described, the compositions consisting essentially of a therapeutically effective quantity of an anti-bacterial agent (such as moxifloxacin), a therapeutically effective quantity of an anti-inflammatory agent (such as triamcinolone), at least one pharmaceutically acceptable excipient and a pharmaceutically acceptable carrier. Methods for fabricating the compositions and using them for intraocular injections are also described. | 01-22-2015 |
| 20150045289 | METHOD OF PRE-PREPARING MEDICATIONS FOR THERAPEUTIC USES - The present invention relates to the method of pre-preparing pharmaceutical compositions for therapeutic uses, particularly pre-preparing medications for treating patients (e.g., cancer patients and the like) by intravenous infusion. | 02-12-2015 |
| 20150080292 | Cyclic lipopeptide antibiotic Locillomycin (Locillomycin-A, Locillomycin-B, Locillomycin-C) and methods of making and using the same - This invention provides new cyclic lipopeptide antibiotic Locillomycin (Locillomycin-A, Locillomycin-B, Locillomycin-C) that display very strong antifungal, antibacterial, antivirus activities in a variety of contexts in vitro; methods of making and using the compounds, wherein Locillomycin-A, Locillomycin-B and Locillomycin-C are derived and purified from the culture of | 03-19-2015 |
| 20150133366 | COMPOSITIONS AND METHODS FOR TREATING CLOSTRIDIUM INFECTION AND PREVENTING RECURRENCE OF INFECTION - infection (CDI) is the most common cause of antibiotic-associated diarrhea. Unfortunately, antibiotic therapy remains as the standard treatment for this antibiotic-induced disease and relapses are common. Antibiotic treatment typically is given for 10 to 14 days for initial or second episode of CDI. For recurrent episodes, more prolonged courses are recommended. It is disclosed herein that lower dose or shorter course of the antimicrobial treatment is sufficient to treat the disease and prevent recurrent disease by enabling a good immunologic response to infection, and perhaps also by better preserving normal flora, thus protecting against relapses or reinfection. | 05-14-2015 |
| 20150141325 | IDENTIFICATION OF INHIBITORS OF A BACTERIAL STRESS RESPONSE - A system, a composition, a method and a kit for identifying anti-bacterial agents are provided. The invention described herein is useful in identifying inhibitors of any bacterial stress response. Moreover, the invention can be applied to any sRNA and its target, any transcription factor and its target, and any transcription factor/sRNA pair (i.e., a transcription factor that regulates a sRNA). In particular, the present invention provides a system, a composition, a method and a kit for the identification of cyclic peptides that block the σ | 05-21-2015 |
| 20150313958 | DAPTOMYCIN FORMULATIONS AND USES THEREOF - Lyophilized daptomycin formulations having improved reconstitution times are provided. The lyophilized daptomycin formulations include an additive, which can be a pharmaceutically acceptable antioxidant, a pharmaceutically acceptable organic acid or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable glucose derivative or a pharmaceutically acceptable salt thereof, or a combination thereof. Also provided are methods of methods of preparing the lyophilized daptomycin formulations, and methods of treating bacterial infections and treating or preventing biofilms by using the lyophilized daptomycin formulations. | 11-05-2015 |
| 20150353607 | Glycopeptide Compound Or Pharmaceutical Salt Thereof And Method For Preparing Same, And Pharmaceutical Compositions And Applications Thereof - The present invention provides a glycopeptide compound or pharmaceutically acceptable salt thereof as shown in Formula (I) or (II), and a method for preparing same, and pharmaceutical compositions and applications thereof, wherein the definition of R | 12-10-2015 |
| 20150374641 | FILM-FORMING PHARMACEUTICAL COMPOSITION FOR WOUND HEALING AND METHOD FOR PREPARING THE SAME - The present invention relates to a pharmaceutical composition for forming a film directly on a wound to accelerate wound healing, a use for the same, a treatment method using the same, and a method for preparing the same. The film-forming composition according to the present invention forms a film directly on the wound to increase the adhesion to the wound. The formed thin hydrophilic film protects the wound surface to prevent infection of the wound surface, retains the physiologically active substance useful for wound healing on the wound surface to promote the wound healing, and allow drugs to be continuously delivered to the wound surface. Therefore, the composition according to the present invention has excellent wound healing effect and has excellent usability as it is not absorbed into clothing, bandage, etc., thus effectively replacing conventional gel or ointment formations for delivering physiologically active substances. | 12-31-2015 |
| 20160009765 | BROAD SPECTRUM ANTIBIOTIC COMPOUNDS AND USE THEREOF | 01-14-2016 |
| 20160030577 | LIPOPEPTIDE COMPOSITIONS AND RELATED METHODS - The present disclosure provides novel powder daptomycin formulations which have improved chemical stability and faster reconstitution times when in the solid state. Some examples of the compositions comprise daptomycin and sucrose. | 02-04-2016 |
| 20160045432 | INTRAOCULAR LENS COMPRISING PHARMACEUTICAL COMPOSITIONS AND METHODS FOR FABRICATING THEREOF - Medical article are described, comprising a lens and a pharmaceutical composition incorporated into the lens, the compositions consisting essentially of a therapeutically effective quantity of an anti-bacterial agent (such as moxifloxacin), a therapeutically effective quantity of an anti-inflammatory agent (such as prednisolone) and at least one pharmaceutically acceptable excipient. Methods for fabricating the medical articles and using them are also described. | 02-18-2016 |
| 20160046674 | ENOPEPTINS, USES THEREOF, AND METHODS OF SNYTHESIS THEREOF - Provided herein are inventive enopeptin compounds of Formula (I): | 02-18-2016 |
| 20160081354 | METHOD FOR TREATMENT OF MICROORGANISMS DURING PROPAGATION, CONDITIONING AND FERMENTATION USING HOPS ACID EXTRACTS AND NISIN - A method of reducing undesirable microorganism concentration, the method comprises (a) introducing a quantity of fermentable carbohydrate to an aqueous system, (b) introducing a quantity of desirable microorganism to the aqueous system, (c) introducing a hops acid extract into the aqueous system and (d) introducing nisin into the aqueous system. | 03-24-2016 |
| 20160082073 | NOVEL USE - The present invention relates to a combination comprising at least one compound selected from the group consisting of an α-adrenergic antagonist, an anthelmintic agent, an antifungal agent, an antimalarial agent, an antineoplastic agent, an antipsychotic agent, an antioxidant, a vasodilator, a vitamin, or a pharmaceutically acceptable derivative thereof; and an antimicrobial compound. | 03-24-2016 |
| 20160082075 | Combination Therapy for Subcutaneous Administration of Glycopeptide Antibiotics - A combination drug therapy is disclosed for the treatment of a patient, such as a human, with a glycopeptide antibiotic. The methods can include subcutaneous administration to a patient of a therapeutically effective amount of a glycopeptide antibiotic, for example, vancomycin, and a compound belonging to the cromones class of anti-inflammatory agents such as cromolyn sodium. The present teachings also provide a therapeutic combination and a kit including the therapeutic combination. | 03-24-2016 |
| 20160082076 | BRIDGE-HELIX CAP: TARGET AND METHOD FOR INHIBITION OF BACTERIAL RNA POLYMERASE - It has been discovered that the Sal target represents a new and promising target for antibacterial drug discovery. The Sal target is distinct from the rifamycin target and from the CBR703 target. This indicates that antibacterial compounds that function through the Sal target should exhibit no, or minimal, cross-resistance with rifamycins and CBR703. This further implies that it should be possible to co-administer antibacterial compounds that function through the Sal target together with a rifamycin, together with CBR703, or together with both a rifamycin and CBR703, in order to achieve additive or synergistic antibacterial effects and in order to suppress or eliminate the emergence of resistance. | 03-24-2016 |
| 20160101118 | PHARMACEUTICAL COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION AND METHODS FOR FABRICATING THEREOF - Pharmaceutical compositions for intraocular injection are described, the compositions consisting essentially of a therapeutically effective quantity of an anti-bacterial agent (such as moxifloxacin), a therapeutically effective quantity of an anti-inflammatory agent (such as prednisolone), at least one pharmaceutically acceptable excipient and a pharmaceutically acceptable carrier. Methods for fabricating the compositions and using them for intraocular injections are also described. | 04-14-2016 |
| 20160101147 | FORMULATIONS OF VANCOMYCIN - Vancomycin-containing compositions substantially free of precipitation after at least about 12 months of storage at refrigerated or ambient conditions are disclosed. The compositions include vancomycin or a pharmaceutically acceptable salt thereof; a polar solvent including propylene glycol, polyethylene glycol and mixtures thereof; lactic acid, a lactate salt, or mixtures thereof; and optionally, a pH adjuster in an amount sufficient to maintain a pH of the compositions at from about 3 to about 8. | 04-14-2016 |
| 20160113919 | CHLOROQUINE STEREOISOMER FOR TREATING TUBERCULOSIS RELATED DISEASES - This disclosure provides a method of treating a subject infected with a mycobacteria of the | 04-28-2016 |
| 20160115136 | COMPOUNDS, COMPOSITIONS COMPRSING SAME, AND METHODS RELATED THERETO - Disclosed herein are compounds, such as benzimidazole derivatives, and composition, such as pharmaceutical compositions, and methods related thereto for treating or preventing microbial infections. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 04-28-2016 |
| 20160120987 | CHEMICAL STRUCTURES FOR LOCALIZED DELIVERY OF THERAPEUTIC AGENTS - The present invention provides a method for selective delivery of a therapeutic or diagnostic agent to a targeted organ or tissue by implanting a biocompatible solid support in the patient being linked to a first binding agent, and administering a second binding agent to the patient linked to the therapeutic or diagnostic agent, such that the therapeutic or diagnostic agent accumulates at the targeted organ or tissue. | 05-05-2016 |
| 20160122386 | V1A RECEPTOR AGONISTS - Compounds of formula (I), salts thereof, and compositions and uses thereof are described. The compounds are useful as V1a vasopressin agonists, for the treatment of, e.g., complications of cirrhosis, including bacterial peritonitis, HRS2 and refractory ascites. | 05-05-2016 |
| 20160129075 | COMPOSITIONS AND METHODS FOR TREATMENT OF CARDIOVASCULAR DISEASE - Provided herein are compositions for the treatment and/or prevention of cardiovascular disease (CVD), and methods of application and use thereof. In particular, the present invention provides treatment and/or prevention of cardiovascular disease with 3,3-dimethyl-1-butanol (DMB) and related compounds, and pharmaceutical formulations thereof. | 05-12-2016 |
| 20160143907 | Methods and Compositions for Treating Clostridium difficile Associated Disease - Methods for treating a subject infected with | 05-26-2016 |
| 20160143941 | NUTRACEUTICAL COMPOSITION AND METHODS FOR PREVENTING OR TREATING MULTIPLE SCLEROSIS - The present invention embraces nutraceutical compositions containing isolated | 05-26-2016 |
| 20160193144 | INTRAOCULAR LENS COMPRISING PHARMACEUTICAL COMPOSITIONS AND METHODS FOR FABRICATING THEREOF | 07-07-2016 |
| 20160200768 | VANCOMYCIN DERIVATIVE, AND PREPARATION METHOD AND APPLICATION THEREOF | 07-14-2016 |
